Protective role of vitamin D status against COVID-19: a mini-review

Maryam Vasheghani1 · Mahsa Rekabi2 · Makan Sadr3

Received: 25 April 2022 / Accepted: 17 September 2022 / Published online: 18 October 2022 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
An outbreak of pneumonia caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is called COVID-19 and has led to a pandemic worldwide. It is reasonable to investigate and control factors affecting disease severity and mortality. The relation between vitamin D and viral pneumonia has been previously reported. Vitamin D deficiency is common and may increase hospital admission and mortality rate in patients with COVID-19. This mini-review examines the pathways that show the association between vitamin D and COVID-19. On the other hand, it deals with the available evidence related to the relationship between vitamin D deficiency and the effect of vitamin D supplementation on the prevalence, severity, and mortality of COVID-19. Also, we described the pathophysiology of the organs’ involvement in COVID-19 and the effect of vitamin D on these outcomes. Vitamin D strengthens the innate and adaptive immune system, modulates immune responses, prevents lung and cardiovascular system damage, and reduces thrombotic events. Vitamin D exerts these effects in several pathways. Vitamin D prevents virus entry and replication by maintaining the integrity of the body’s physical barrier. Vitamin D reduces the damage to vital organs and thrombotic events by increasing the level of Angiotensin-converting enzyme 2 (ACE2), nitric oxide, and antioxidants or by reducing inflammatory cytokines and free radicals. Sufficient vitamin D may be reduced morbidity and mortality due to COVID-19. However, this issue should be investigated and confirmed by further research in the future.

Keywords COVID-19 · Vitamin D · Immune system · Respiratory · Cytokines

Introduction
At the end of 2019, pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported from Wuhan, China. The World Health Organization (WHO) called this pandemic disease as COVID-19. This disease had high morbidity and mortality and became a great challenge for governments and health systems. As of August 26, 2022, 596,873,121 definitive cases of COVID-19 have been reported to the WHO, of which 6,459,684 have died [1]. The incubation period of this disease is usually about 5–6 days. Most people infected with SARS-CoV-2 have mild to moderate symptoms of respiratory illness and recover with outpatient management and supportive measures. Symptoms such as fever, cough, fatigue, loss of taste or smell, sore throat, headache, myalgia, diarrhea, skin rash, and red eyes are common. However, some patients experience severe symptoms (such as shortness of breath, impaired consciousness, and chest pain) and require medical care. The severe form of the disease is more common in the elderly and those with underlying diseases such as cardiovascular disease, diabetes mellitus, chronic respiratory disease, and cancer. A small number of patients develop complications including acute respiratory distress, pulmonary thromboembolism, deep vein thrombosis, and vasculitis which may even lead to death [2–5].

Multiple treatment strategies are available for COVID-19. Treatment options vary depending on individual characteristics, disease severity, co-morbidities, and access of patients to health services. Treatment goals include preventing the disease
progression, complications as well as reducing mortality. The National Institutes of Health (NIH) has published guidelines in this regard and its recommendations differ depending on whether it is outpatient or inpatient [6]. Antiviral agents such as remdesivir and immune system modulating drugs (such as dexamethasone and monoclonal antibodies) and antithrombotic drugs (such as low molecular weight heparin) can prevent disease progression and reduce mortality [7–10]. Five anti-SARS-CoV-2 monoclonal antibody products have received emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the United States. The authorized anti-SARS-CoV-2 monoclonal antibody products which are currently available for use include Tocilizomab, Breetelovimab, Tixagevimab plus Cilgavimab, Bamlanivimab plus Etelvimab, Casirivimab plus Edelevimab, and Sotrovimab [6, 11].

At present, COVID-19 control is performed by health measures, quarantine, and vaccination. New SARS-CoV-2 variants such as Delta and Omicron have appeared due to mutations in the virus genome. These new variants have also been able to create a pandemic [12]. The existing vaccines can probably prevent the severity of the disease and death caused by these new variants. However, there are still concerns about the effectiveness of existing vaccines against new variants of the virus [13–16]. The physicians and researchers continue to identify risk factors, common and rare signs and symptoms of COVID-19, and the complications to control the disease and to reduce the mortality rate of COVID-19 [17–20].

The role of vitamin D in the control of pneumonia caused by viral agents such as influenza A and SARS has already been mentioned [21, 22]. COVID-19 is more prevalent and severe in higher latitude area and is more common in people who are more likely to have vitamin D deficiency, such as elderly and diabetics [23–25]. People with COVID-19 have a low serum level of 25 hydroxyvitamin D (13 ng/dl) and the prevalence of this vitamin deficiency is 45% in a study from Armenia [26]. There is an inverse relationship between serum 25 hydroxyvitamin D levels and the severity of COVID-19 [27, 28]. Vitamin D deficiency has increased hospital admission [odds ratio (OR) = 1.81, 95% confidence interval (CI) = 1.41–2.21] and mortality rate from COVID-19 (OR = 1.82, 95% CI = 1.06–2.58) in some studies [29]. Vitamin D supplementation may be reduced COVID-19 severity and mortality rate. In the clinical trials, vitamin D supplementation in hospitalized patients with covid-19 reduced the use of non-invasive ventilation and the level of inflammatory markers. Vitamin D supplementation also reduced the mortality rate in the case group by 50% compared to the control group [30–32]. Vitamin D can reduce the risk of viral infections and possibly COVID-19, its complications and mortality rate by various mechanisms. In this review, some of these mechanisms will be explained. A summary of these associations is shown in Fig. 1.

**Vitamin D and body defense barrier and virus replication**

The epithelial cells in the respiratory tract protects us as a physical barrier from pathogens invasions. The active metabolite of vitamin D (1, 25-dihydroxyvitamin D) upregulate genes that encode proteins such as Occludin, Connexin 43 and E-cadherin. These proteins are needed for tight junctions, as well as gap and adherent junctions, respectively. In this way, vitamin D can prevent the entry of pathogens and thus prevent lung infections [33].

The effect of vitamin D on the proliferation of respiratory viruses has been different in various studies. In the in vitro studies, replication and release of rhinovirus is reduced by 1, 25-dihydroxyvitamin D (1, 25(OH) 2 vitamin D). Downregulation of vitamin D receptor increases rhinovirus replication [34]. But in another study, 1, 25(OH) 2 vitamin D didn’t decrease virus replication. Instead, 1, 25(OH) 2 vitamin D and 25 hydroxyvitamin D (25O HVitamin D) caused significant thickening of the cell layers and proliferation of cytokeratin-5-expressing cells in respiratory epithelium. Thus, vitamin D prevents the virus entry to the lung epithelium by strengthening the physical-defensive barrier and does not inhibiting the virus replication [35].

**Vitamin D and immune system modulation**

Immune responses to pathogens fall into two main categories: (a) intrinsic responses in which neutrophils, macrophages, and NK cells respond rapidly and specifically to the pathogen; and (b) adaptive responses in which T and B lymphocytes respond with a delay and slower but more specific to the pathogen. The effects of COVID-19 virus on the immune system have not been fully explained. Immune responses to COVID-19 have ceased in the innate immune phase and do not make sufficient progress toward adaptive immunity. Imbalances in the immune system reduce the innate immune response to pathogen and in turn disproportionately increase the production of cytokines and inflammatory factors. This imbalance intensifies the severity of the disease and consequently the mortality rate due to COVID-19 [36].

Vitamin D receptor (VDR) is expressed in almost all immune cells, including activated T cell with cluster of differentiation 4 (CD4+ T cells) and CD8+ T cells, B cells, and antigen-presenting cells (such as macrophages and dendritic cells). Vitamin D has two important effects on the immune system. Strengthens the immune system against pathogens and reduces the rate of respiratory infections. It also prevents over-activation of the immune system and reduces autoimmune diseases as well as cytokine storms. First, the immunomodulatory role of vitamin D is applied to
the both innate and secondary immune system. Vitamin D interacts with the innate immune system, by activating Toll-like receptors (TLRs) or increasing the levels of antimicrobial peptides (AMPs) such as cathelicidins and β-defensins by activating immune cells. Cathelicidins inactivate viruses such as Influenza A virus by destroying envelope proteins. A primary form of cathelicidins is known as LL-37, which prevents the virus from entering the cell. Also, LL-37 significantly increases H2O2 production within neutrophils in the response to virus entry. CD8+ T cells, which express high level of VDR, proliferate rapidly and kill infected cells by inducing apoptosis. Second, Vitamin D interacts with the adaptive immune system. Vitamin D reduces immunoglobulin which is secreted by plasma cells and pro-inflammatory cytokines production; thus, modulates T cells function. Vitamin D also promotes self-tolerance by shifting the differentiation pathway of helper T cells (TH) towards TH2 production, and the number of TH1 decreases. As a result, the production of inflammatory cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), IL-8, IL-9, IL-12, and IL-17 reduces by decreasing CD4$^+$& CD8$^+$ T cells. Meanwhile, the production of anti-inflammatory factors such as IL-4, IL-5, and IL-10 from TH2 cells increases. CD8+ T cells, which express high level of VDR, proliferate rapidly and kill infected cells by inducing apoptosis [37–40]. These mechanisms are summarized in Fig. 2.

**Vitamin D and lung injury in COVID-19**

SARS-CoV-2 enters host lung cells through the angiotensin-converting enzyme (ACE) protein in the cell membrane. Binding of viral spikes protein to ACE2 receptor results in its downregulation and the level of ACE2
level decreases. Because ACE2 protects the lungs from injury, ACE2 deficiency may expose patients to lung damage. Due to the protective effect of ACE2 receptor in preventing lung injury, deficiency of this receptor may expose the patient to lung damage. Several factors may affect the entry of SARS-CoV-2 into the cell through ACE2. There is evidence that the ACE inhibitors or angiotensin receptor blockers (ARBs) increase the risk of COVID-19 [41, 42]. Vitamin D can increase ACE2 levels by two mechanisms and may protect the lung from COVID-19-induced damage. Vitamin D independently increases ACE2 gene expression. In addition, vitamin D suppresses the compensatory increase in renin levels following inhibition of the renin-angiotensin system and causes an increase in ACE2 [43].

In COVID-19, ACE2 downregulation leads to unopposed inflammatory chain-reaction, cytokine storm (i.e. generation of both pro-inflammatory and anti-inflammatory cytokines by innate immune system) and lethal acute respiratory distress syndrome (ARDS). Vitamin D reduces lung permeability in animal models of ARDS by modulating renin-angiotensin system (RAS) activity and ACE2 gene expression [44].

Although most studies have suggested the role of ACE2 in COVID-19, but there are studies in which serum ACE levels are also low. In this study, the levels of vitamin D and ACE in patients with severe COVID-19 have been lower than in mild cases and have been associated with worse outcomes [45]. The score of lung involvement on computed tomography (CT) Scan of the Chest has an inverse
relationship with to the mean serum level of vitamin D in hospitalized patients with COVID-19 [46].

Another study examined the effect of vitamin D on hyperoxia-induced lung damage in newborn rats. Vitamin D has been able to reduce the lung damage caused by excessive oxygen administration by maintaining the integrity of the lung structure, reducing inflammation, reducing the deposition of extracellular matrix, and inhibiting lung cell apoptosis [47]. Vitamin D deficiency causes RAS overactivation and extracellular matrix deposition and resulting in pulmonary fibrosis and impaired lung function [48]. Vitamin D supplementation reduces the number of CD8+ and invariant mucosal T cells and may prevent the progression of lung damage associated with cystic fibrosis [49].

**Vitamin D and cardiovascular involvement in COVID-19**

Cardiovascular diseases such as hypertension and ischemic heart disease have been reported as risk factors for COVID-19. Arrhythmias, myocardial infarction, and thromboembolic events are also important causes of mortality in COVID-19 patients. On the other hand, vitamin D has a protective role in cardiovascular diseases. Vitamin D exerts its protective effects on the cardiovascular system in several different ways. Activation of the vitamin D receptor by regulating the entry of calcium into myocytes causes myocardial contraction and affects the contractility of the heart. Vitamin D may inhibit the formation or progression of atherosclerotic plaques by inhibiting the conversion of macrophages to foam cells and by increasing cholesterol efflux, and thus, protects against atherosclerosis. 1,25(OH)2 vitamin D repairs vascular endothelium by producing vascular endothelial growth factor in vascular smooth muscle cells. Vitamin D reduces inflammation in the vascular endothelium by decreasing nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and IL-6. Vitamin D reduces vascular thrombosis by decreasing tissue factor 3 and increasing thrombomodulin in endothelial cells and macrophages. Vitamin D also increases nitric oxide in vascular endothelium and protects them. However, there is evidence that high levels of vitamin D increase vascular calcification and atherosclerotic disease [50].

Vitamin D deficiency is associated with hypertension, ischemic heart disease, diabetes mellitus and obesity. Both vitamin D deficiency and the above mentioned diseases are also associated with COVID-19 [51]. This relationship may be a simple, coincidental association, or in the context of an unknown pathophysiology that explains these relationships, or they may have a cause-and-effect relationship. These relationships are not well understood at present, and further fundamental and applied studies in the future may answer these questions.

**Vitamin D supplementation and COVID-19**

Vitamin D deficiency (25 hydroxyvitamin D < 50 nmol/L) is common and has affected more than one-third of the population worldwide [52]. Several systematic reviews and Meta-analyses have evaluated the role of vitamin D Supplementation in the prevention of respiratory infections in randomized controlled clinical trials. Vitamin D had a protective effect against respiratory infections (OR = 0.64; 95% CI = 0.49–0.84). The protective effect of vitamin D in studies that used oral doses between 1000 and 4000 international unit (IU) per day was greater than the intramuscular bolus injection dose of 100,000 IU per month (OR = 0.51 vs. OR = 0.86, P = 0.01) [53]. In a clinical case series, the effect of vitamin D supplementation on patients with COVID-19 was evaluated in two groups, high dose group (Ergocalciferol 50,000 IU daily) and standard dose group (Cholecalciferol 1000 IU daily) for 5 days. In high dose group, vitamin D levels returned to normal earlier and they had better clinical outcome. The hospital length stays, oxygen requirements, and inflammatory markers were lower in this group [54]. At present, experts have different opinions in this regard. To reduce the risk of infection, they recommend that people at risk for influenza A and/or COVID-19 take 10,000 IU of vitamin D daily for a few weeks and then 5000 IU daily to increase vitamin D levels rapidly. The goal should be to increase the concentration of 25 (OH) D above 40–60 ng/ml (100–150 nmol/L). Higher doses of vitamin D3 may be helpful in treating people who become infected with COVID-19. However, to evaluate these recommendations, randomized controlled clinical trials and numerous population studies should be performed [55–58].

**Conclusion**

Vitamin D can protect body against COVID-19 through several main mechanisms. Vitamin D strengthens the innate and adaptive immune system, modulates immune responses, prevents lung and cardiovascular system damage, and reduces thrombotic events. Vitamin D deficiency can be a risk factor for COVID-19 infection and its severity. Vitamin D supplementation may be effective in improving the clinical outcome and reducing morbidity and mortality rate due to COVID-19. However, these issues should be investigated and confirmed by further research in the future.

**Data availability**

All the data obtained during this study are published in this article.
Acknowledgements The authors dedicate this article to physicians, nurses, and medical personnel who have sacrificed their lives to care for patients with COVID-19.

Author contributions M.V. designed the project, searched, reviewed and selected different articles, wrote the initial draft of the article, wrote and edited the final format of the article. M.R. wrote and edited the immunology issue and drew figures 1 and 2. M.S. supervised the investigation. He reviewed and edited the manuscript.

Compliance with ethical standards

Conflict of interest The authors declare no competing interests.

Consent for publication The authors would like to submit this review article entitled “Protective role of vitamin D status against COVID-19: A Mini-Review” for consideration by the “Endocrine, International Journal of Basic and Clinical Endocrinology”. The authors certify that this study is original and has not been published elsewhere, and is not currently under review elsewhere.

Ethics In this review article, the authors have referred to appropriate and relevant literature in support of the content presented in it.

References

1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard/Overview (2022). https://covid19.who.int/
2. N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020)
3. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020)
4. J.J. Zhang, X. Dong, Y.Y. Cao, Y.B. Yang, Y.Q. Yan et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy 75, 1730–41. (2020)
5. C. Wang, P.W. Horby, F.G. Hayden, G.F. Gao, A novel coronavirus outbreak of global health concern. Lancet 395, 470–473 (2020)
6. National Institutes of Health. Home. COVID-19 Treatment Guidelines/Therapies. https://www.covid19treatmentguidelines.nih.gov/
7. V. Bansal, K.S. Mahapure, A. Bhurwal, I. Gupta, S. Hassamain, J. Makadia, N. Madas, P. Armany, R. Singh, I. Mehra, J.C. O’Horo, R. Kashyap, Mortality benefit of remdesivir in COVID-19: a systematic review and meta-analysis. Front. Med. 27(7), 606429 (2021). https://doi.org/10.3389/fmed.2020.606429
8. RECOVERY Collaborative Group, P. Horby, W.S. Lim, J.R. Emberson, M. Mathem, J.L. Bell, L. Linsell, N. Staplin, C. Brightling, A. Uistansowski, E. Elmahia, B. Prudon, C. Green, T. Felton, D. Chadwick, K. Rege, C. Fegan, L.C. Chappell, S.N. Faust, T. Jaki, K. Jeffery, A. Montgomery, K. Rowan, E. Juszczyk, J.K. Baillie, R. Haynes, M.J. Landray, Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384(8), 693–704 (2021). https://doi.org/10.1056/NEJMoa2021436
9. M. Mazzitelli, E. Arriggi, F. Serapide, M.C. Pelle, B. Tassone, R. Lionello, G. Marrazzo, D. Laganà, F.S. Costanzo, G. Matera, E.M. Trecarichi, C. Torti. Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. J. Med Virol. 93(1), 32–34 (2021). https://doi.org/10.1002/jmv.26016
10. A. De Vito, L. Saderi, V. Fiore, N. Geremia, E. Princic, C. Fanelli, A.A. Muredda, C.P. Napodano, G. M. I. Maida, A.G. Fois, G. Sotgiu, G. Madeddu, S. Babudieri, Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients. Panminerva Med. (2022). https://doi.org/10.23736/S0031-0808.22.04572-4
11. Food and Drug Administration. Home. Emergency preparedness and response. Counterterrorism and emerging threats. Coronavirus disease 2019 (COVID-19)/Emergency Use Authorizations (EUAs)/Drugs and Non-Vaccine Biological Products. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-a-authorization#coviddrugs
12. S.F. Mousavi, M. Ebrahimi, S.A.A. Moghaddam, N. Moaﬁ, M. Jafari, A. Tavakolian, M. Heidary, Evaluating the characteristics of patients with SARS-CoV-2 infection admitted during COVID-19 peaks: A single-center study. Vacunas (2022), https://doi.org/10.1016/j.vacun.2022.08.002
13. L. Hu, Y. Xu, L. Wu, J. Feng, L. Zhang, Y. Tang, X. Zhao, R. Mai, L. Chen, L. Mei, Y. Tan, Y. Du, Y. Zhen, W. Su, T. Peng. The E484K substitution in a SARS-CoV-2 spike protein subunit vaccine resulted in limited cross-reactive neutralizing antibody responses in mice. Viruses 14(5), 854 (2022). https://doi.org/10.3390/v14050854
14. A. Kuzmina, S. Wattad, S. Engel, E. Rosenberg, R. Taube, Functional analysis of spike from SARS-CoV-2 variants reveals the role of distinct mutations in neutralization potential and viral infectivity. Viruses 14(4), 803 (2022). https://doi.org/10.3390/v14040803
15. S. Sun, J. Wu, R. Chen, M. Levitt, SARS-CoV-2 Omicron variant: viral spread dynamics, disease burden, and vaccine effectiveness. Curr. Med. 1(1), 14 (2022). https://doi.org/10.1007/s44194-022-00014-x
16. P.J. Macdonald, J.M. Schaub, Q. Ruan, C.L. Williams, J.C. Prostko, S.Y. Tetin, Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines. Commun. Med. 2, 109 (2022). https://doi.org/10.1038/s43856-022-00174-9
17. J. Berenguer, A.M. Borobia, P. Ryan, J. Rodríguez-Baño, J.M. Bellón, I. Jarrín, J. Carratala, J. Pachón, A.J. Carcas, M. Yellescas, J.R. Arribas, COVID-19/Span and COVID@HULP Study Groups. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax 76(9), 920–929 (2021). https://doi.org/10.1136/thoraxjnl-2020-216001
18. T. Meister, H. Prostko, R. Kolde, R. Kalda, K. Suija, L. Milani, L. Karo-Astover, M. Piirsoo, A. Uusküla, Clinical characteristics and risk factors for COVID-19 infection and disease severity: a nationwide observational study in Estonia. PLoS ONE 17(6), e0270192 (2022). https://doi.org/10.1371/journal.pone.0270192
19. S. Karapetyan, A. Schneider, K. Linde, E. Donnachie, A. Hafelfmeier, SARS-CoV-2 infection and cardiovascular or pulmonary complications in ambulatory care: a risk assessment based on routine data. PLoS ONE 16(10), e0258914 (2021). https://doi.org/10.1371/journal.pone.0258914
20. M. Sadat Larijani, F. Ashrafi, F. Bagheri Amiri, M. Banifazl, A. Bavand, A. Karami, F. Asgari Shokooh, A. Ramezani, Characterization of long COVID-19 manifestations and its associated factors: a prospective cohort study from Iran. Micro. Pathog. 169, 105618 (2022). https://doi.org/10.1016/j.micpath.2022.105618
21. A. Zittermann, S. Pilz, H. Hoffmann, W. März, Vitamin D and airway infections: a European perspective. Eur. J. Med Res. 21, 14 (2016). https://doi.org/10.1186/s40001-016-0208-y
22. G. Schwalfenberg, Vitamin D for influenza. Can. Fam. Physician 61(6), 507 (2015)
23. P.C. Ilie, S. Stefanscuc, L. Smith, The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin. Exp. Res. 32(7), 1195–1198 (2020). https://doi.org/10.1007/s40520-020-01570-8

24. D.M. McCartney, D.G. Byrne, Optimization of vitamin D status for enhanced immuno-protection against COVID-19. Ir. Med J. 113(4), S8 (2020)

25. W.B. Grant, H. Lahore, S.L. McDonnell, C.A. Baggerly, C.B. French, J.L. Aliano, H.P. Bhattoa, Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 Infections and Deaths. Nutrients 12(4), E988 (2020). https://doi.org/10.3390/nu12040898

26. N. Hutchings, V. Babalayan, S. Baghdasaryan, M. Qefoyan, N. Sargsyants, E. Aghajanova, A. Martirosyan, R. Harutyunyan, O. Lesnyak, A.M. Formenti, A. Giustina, J.P. Bilezikian, Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. Endocrine 71(2), 267–269 (2021). https://doi.org/10.1007/s12020-020-02597-7

27. V. Baktash, T. Hosack, N. Patel, S. Shah, P. Kandiah, K. Van den Abbeele, A.K.J. Mandal, C.G. Missouris, Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad. Med J. 97(1149), 442–447 (2021). https://doi.org/10.1136/postgradmedj-2020-137122

28. F. Yasari, M. Akbarian, A. Abedini, M. Vasheghani, The role of electrolyte imbalances in predicting the severity of COVID-19 in the hospitalized patients: a cross-sectional study. Sci. Rep. 30 (12), 14732 (2022). https://doi.org/10.1038/s41598-022-19264-8

29. M. Pereira, A. Dantas Damascena, L.M. Galvão Azevedo, T. de Almeida Oliveira, J. da Mota Santana, Vitamin D deficiency induces lung inflammation: Effect of vitamin D depletion or supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: Extension phase of the GERIA-COVID study. J. Steroid Biochem Mol. Biol. 213, 105958 (2021). https://doi.org/10.1016/j.jsbmb.2021.105958

30. F. Viore, A. De Vito, P. Bagella, E. Princic, A.A. Mariani, L. Denti, A.G. Fois, G. Mageddu, S. Babudieri, I. Maida, Vitamin D deficiency induces lung injury: Protective common molecular mechanisms of vitamin D deficiency in COVID-19. J. Steroid Biochem Mol. Biol. 213, 105958 (2021). https://doi.org/10.1016/j.jsbmb.2021.105958

31. C. Annweiler, M. Beaudenon, R. Simon, M. Guenet, M. Otekpo, G.K. Schwalfenberg, A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Mol. Nutr. Food Res. 55(1), 96–108 (2011). https://doi.org/10.1002/mnfr.201000174

32. A.G. Telcian, M.T. Zidrenga, M.R. Edwards, V. Laza-Stanca, P. Mallia, S.L. Johnston, L.A. Stanciu, Vitamin D decreases the antioxidant activity of bronchial epithelial cells in vitro. Antivir. Res. 137, 93–101 (2017). https://doi.org/10.1016/j.antiviral.2016.11.004

33. I. Chiocia, D. Gatti, D. Soranna, D. Merlotti, C. Mingiano, A. Fassio, G. Adami, A. Falchetti, C. Eller-Vainicher, M. Rossini, L. Persani, A. Zambon, L. Gennari, Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes. Front Public Health 9, 736665 (2021). https://doi.org/10.3389/fpubh.2021.736665

34. G.K. Schwalfenberg, A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Mol. Nutr. Food Res. 55(1), 96–108 (2011). https://doi.org/10.1002/mnfr.201000174

35. A.G. Telcian, M.T. Zidrenga, M.R. Edwards, V. Laza-Stanca, P. Mallia, S.L. Johnston, L.A. Stanciu, Vitamin D decreases the antiviral activity of bronchial epithelial cells in vitro. Antivir. Res. 137, 93–101 (2017). https://doi.org/10.1016/j.antiviral.2016.11.004

36. R.A. Brockman-Schneider, R.J. Pickles, J.E. Gem, Effects of vitamin D on airway epithelial cell morphology and rhinovirus replication. PLoS ONE 9(1), e86755 (2014). https://doi.org/10.1371/journal.pone.0086755

37. M.V. Blagoslonskny, From causes of aging to death from COVID-19. Aging 12(11), 10004–10021 (2020). https://doi.org/10.18632/aging.103493. Jun 12
51. M. Puig-Domingo, M. Marazuela, B.O. Yildiz, A. Giustina, COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine 72(2), 301–316 (2021). https://doi.org/10.1007/s12020-021-02734-w

52. D.E. Roth, S.A. Abrams, J. Aloia, G. Bergeron, M.W. Bourassa, K.H. Brown, M.S. Calvo, K.D. Cashman, G. Combs, L.M. De-Regil, M.E. Jeffers, K.S. Jones, H. Kapner, A.R. Martineau, L.M. Neufeld, R.L. Schleicher, T.D. Thacher, S.J. Whiting, Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. Ann. N. Y. Acad. Sci. 1430(1), 44–79 (2018). https://doi.org/10.1111/nyas.13968

53. P. Bergman, A.U. Lindh, L. Björkhem-Bergman, J.D. Lindh, Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 8(6), e65835 (2013). https://doi.org/10.1371/journal.pone.0065835

54. K.C. Ohaegbulam, M. Swail, P. Patel, M.A. Smith, R. Perrin, Vitamin D supplementation in COVID-19 patients: a clinical case series. Am. J. Ther. 27(5), e485–e490 (2020). https://doi.org/10.1097/MJT.0000000000001222

55. M.T. Aslan, İ.Ö. Aslan, Ö. Özdemir, Letter to the Editor: Is vitamin D one of the key elements in COVID-19 days? J. Nutr. Health Aging 24(9), 1038–1039 (2020). https://doi.org/10.1007/s12603-020-1413-5

56. B. Gui, Q. Chen, C. Hu, C. Zhu, G. He, Effects of calcitriol (1, 25-dihydroxy-vitamin D3) on the inflammatory response induced by H9N2 influenza virus infection in human lung A549 epithelial cells and in mice. Virol. J. 14(1), 10 (2017). https://doi.org/10.1186/s12985-017-0683-y

57. M. Urashima, T. Segawa, M. Okazaki, M. Kurihara, Y. Wada, H. Ida, Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 91(5), 1255–1260 (2010). May 1

58. F. Momplaisir, I. Frank, W. Meyer 3rd, D. Kim, R. Kappes, P. Tebas, Vitamin D levels, natural H1N1 Infection and Response to H1N1 vaccine among HIV-infected individuals. J AIDS Clin. Res. 3(4), 152 (2012). https://doi.org/10.4172/2155-6113.1000152

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.